Difference between revisions of "Riebel V"
From Bioblast
Purtschera (talk | contribs) |
Beno Marija (talk | contribs) |
||
| Line 1: | Line 1: | ||
{{Person | {{Person | ||
|lastname=Riebel | |||
|firstname=Virginie | |firstname=Virginie | ||
| | |institution=Novartis Pharma AG, Werk Klybeck | ||
|area code=CH-4002 | |||
|city=Basel | |||
|country=Switzerland | |||
|mailaddress=virginie.riebel@novartis.com | |mailaddress=virginie.riebel@novartis.com | ||
}} | }} | ||
{{Labelingperson}} | |||
==Participated at== | |||
::::*[[IOC39]] | |||
Revision as of 15:50, 31 May 2017
| Name | Riebel Virginie, |
|---|---|
| Institution | Novartis Pharma AG, Werk Klybeck |
| Address | , CH-4002 |
| City | Basel |
| State/Province | |
| Country | Switzerland |
| virginie.riebel@novartis.com | |
| Weblink | |
| O2k-Network Lab | CH Basel Uteng M |
Labels:
Publications
| Published | Reference | |
|---|---|---|
| Brecht 2016 Toxicol In Vitro | 2016 | Brecht K, Riebel V, Couttet P, Paech F, Wolf A, Chibout SD, Pognan F, Krähenbühl S, Uteng M (2016) Mechanistic insights into selective killing of OXPHOS-dependent cancer cells by arctigenin. Toxicol In Vitro 40:55-65. |
